Jefferies Starts Ra Pharma (RARX) at Buy

November 21, 2016 6:51 AM EST
Get Alerts RARX Hot Sheet
Price: $15.79 +6.91%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade RARX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies initiates coverage on Ra Pharma (NASDAQ: RARX) with a Buy rating and a price target of $25.00.

Analyst Eun Yang commented, "Utilizing its peptide chemistry platform, RARX focus on complement-mediated diseases. Given well-validated C5 target & encouraging Ph1 data, we view lead candidate RA101495 as somewhat de-risked. Key catalyst is Ph2 data for RA101495 in PNH pts in 2H17; if positive (similar to Soliris), we view >100% potential upside as likely from current levels. RA101495 could potentially be a convenient, SC alternative to ALXN's Soliris (~$2.9B in 2016E sales)."

For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.

Shares of Ra Pharma closed at $13.29 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment